

Award Number: W81XWH-15-1-0121

TITLE:

Systematic Identification of Genes Required for Expression of Androgen Receptor
Splice Variants

PRINCIPAL INVESTIGATOR: Yin-Yuan Mo

CONTRACTING ORGANIZATION:

University of Mississippi Medical Center
Jackson, MS 39216

REPORT DATE: August 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE August 2016		2. REPORT TYPE Final		3. DATES COVERED 1 Jun 2015 - 31 May 2016	
4. TITLE AND SUBTITLE Systematic Identification of Genes Required for Expression of Androgen Receptor Splice Variants				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-15-1-0121	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yin-Yuan Mo E-Mail: ymo@umc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Mississippi Medical Center 2500 State Street, G652 Jackson, MS 39216				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Recently, a new genetic engineering tool has been developed from bacterial Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated System (Cas). It has several advantages over the existing ones and one of them is the ability to make a very large number (tenth of thousands) of gene knockouts so that we can screen genes important to prostate cancer. For example, androgen receptor (AR) is well known for its role in prostate cancer progression and castration resistance, and several AR splicing variants have been identified in castration resistant prostate cancer. With this technology, we can answer questions like how prostate cancer becomes castration resistant after anti-hormone therapy. Furthermore, these genes screened out with this technology may serve biomarkers or therapeutic targets. Thus, the overall goal of this application is to identify genes involved in regulation of AR splice variant through CRISPR/Cas screening system.					
15. SUBJECT TERMS CRISPR/Cas, Androgen receptor, castration resistance, biomarker					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	23	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusion.....	8
References.....	8
Appendices.....	10

Introduction

Androgen receptor (AR) plays a critical role in prostate development and prostate cancer pathogenesis. Thus AR is a major therapeutic target for prostate cancer. For example, androgen deprivation is a frontline treatment for aggressive prostate cancer. These tumor cells respond well to such treatment, however, in the long run many patients develop anti-hormone resistance, in part due to expression of constitutively active AR splice variants. At least 7 AR variants have been identified to date and AR3 is one of the major AR splice variants identified in prostate cancer cell lines and human prostate cancer tissue.

However, the underlying mechanism of how AR splice variants are regulated is still not fully understood. To better understand how expression of AR splice variants is regulated, we propose to perform a genome wide gene knockout screening will provide a systematical identification of genes involved in expression of a specific AR splice variant. In this application, we focus on AR3, a predominant variants that has been shown to be expressed in prostate cancer tissue and castration resistant prostate cancer cell lines. To achieve this, we generate a reporter system that will allow the cells carrying a specific gene knockout to survive when AR3 splicing takes place.

Body

Results

The full length AR is expressed through direct connection of E3 with E4 (Fig. 1), as seen in androgen sensitive LNCaP cells. On the other hand, AR3 is derived from through

direct connection of exon 3 (E3) and E3b, as seen in castration resistant CWR22Rv1 cells. Since AR3 is a predominant variant expressed in clinical specimens and prostate cancer cell lines, and it plays a significant role in castration resistance, we focus on AR3 in this application with two major tasks as follows.




Fig. 1 Expression of AR splice variants

Task 1. Generate a reporter system for full-length AR and AR3 (all subtasks completed)

- Two set of reporters will be constructed in this application: 1) E3b reporter for AR3 expression and 2) E4 reporter for full-length AR. **done**
- E3b reporter will be constructed by amplifying the following fragments using the high fidelity enzyme Phusion: EF1 promoter, E3-intron, intron E3b, mCherry-T2A-BSR. **done**
- To construct E4 reporter, we will first amplify intron-E4 fragment to replace intron-E3b. **done**
- These fragments will be cloned into a lentiviral vector by Gibson Assembling method. **done**
- We will test each of reporters in LNCaP and CWR22Rv1 cells, respectively. **See Task 2**

To identify genes required for the full length AR or AR3, we took advantage of genome-wide gRNA library (GeCKO library) which consists of 122,417 unique guide sequences

targeting 19,052 human genes and including 1000 control (non-targeting) gRNAs available from Addgene (<http://www.addgene.org/CRISPR/libraries/>).

Generation of AR3 reporter: We used molecular cloning approach to generate AR3 reporter as shown in Fig. 2. This reporter carries the EF1 promoter (EF1), E3, E3b and mCherry-T2A-Blast. In addition, it also carries an intron between E3 and E3b. Therefore, this reporter enabled us to identify which gene knockout that can lead to expression of AR3 (Fig.2).




Fig. 2 Description of AR reporter used in screening experiments.

Task 2. Selection and validation (all subtasks completed)

- We will make stable infected LNCaP and CWR22Rv1 carrying GeCKO gRNA library and LentiCRISPR (vector alone), respectively. **done**
- Screening will be performed for each reporter separately. **done**
- We will first introduce E3b reporter into LNCaP cells and then perform selection against blasticidin. **done**
- We expect that after selection, much more surviving colonies will form from the library than vector control, an enrichment process. **done**
- We will pool all surviving colonies and extract genomic DNA. **done**

- f. PCR amplification using primers flanking gRNAs. **done**
- g. Deep sequencing for PCR products. **done**
- h. Data analysis to identify enriched gRNA sequences (library vs vector control) **done**
- i. The same procedure will be applied to E4 reporter. **done**
- j. To rule out any false positive, we will validate these enriched gRNAs by re-introducing each or mixed gRNAs into the same cells and repeat the same selection procedure. **done**
- k. We will further verify them by examining endogenous full length AR and AR3 through qRT-PCR and Western blot. **done**

In this task, we first established stable LNCaP transductants carrying GeCKO library and Cas9, and we then introduced AR3 reporter, followed by selection of blasticidine resistant colonies (Fig. 3).

We introduced GeCKO gRNA library and LentiCRISPR (vector alone), respectively, into LNCaP cells by infection and then selected stable cells in the presence of puromycin. The AR3 reporter was then introduced into these stable cells by infection. We performed selection against blasticidin. Ten days after selection, we found more surviving colonies from the library as compared to vector control. To determine which gRNAs are enriched, we extracted genomic DNA from surviving cells and then performed PCR amplification using primers flanking gRNAs. Deep sequencing and data analysis identified a few enriched gRNA sequences, and among them was hnRNP A1.




Fig. 3 Identification of AR3 negative regulators through knockout using Gecko gRNA library in LNCaP cells.

Identification of hnRNP A1 as an AR3 negative regulator: Since hnRNP A1 is well-known for its role in mRNA processing or alternative splicing (1, 2), and it may function as a splicing silencer factor (3), we took three approaches to determine whether hnRNP A1 is a true negative regulator for AR3 expression. First, we found two putative hnRNP A1 binding sites (4) in the intron between exon 3 (E3) and exon 3b (E3b). Thus, we used an hnRNP A1 winner sequence (UAUGAUUAGGGACUUAGGGUG) with two putative binding sites (underlined) based on literature report (4). As expected, this A1 winner oligo was able to increase AR3 expression in R22Rv1 cells as compared to control oligo (Fig. 4, left). Second, we knocked down hnRNP A1 by siRNA (Fig. 4, middle) and found hnRNP A1 by siRNA was able to enhance AR3 expression. Finally, we knocked out hnRNP A1 by CRISPR/Cas9 (Fig. 4, right), which caused upregulation of AR3 expression in R22Rv1 cells. Together, these results support a suppressive role of hnRNP

A1 in AR3 expression. The following Fig. 4 is derived from Fig. 4A of our published Oncotarget paper.




Fig. 4 Identification of hnRNP A1 (A1) as an AR3 negative regulator. An increase in AR3 expression by A1 winner oligo (left), A1 siRNA (middle) or A1 KO (right).

Key Research Accomplishments

- We successfully generated a AR splice variant reporter system
- Through this study, we established a screening platform for identification of AR splice variants
- We identified hnRNP A1 as a potential AR3 negative regulator
- Further characterization demonstrated that hnRNP A1 regulates AR splicing through two hnRNP A1 binding sites in the AR intron between E3 and E3b
- Additional studies suggest that long non-coding RNAs such as PCGEM1 can play a positive regulatory role in AR expression.

Reportable Outcomes

This work was published in Oncotarget

Zhang Z, Zhou N, Huang J, Ho TT, Zhu Z, Qiu Z, Zhou X, Bai C, Wu F, Xu M, Mo YY.

Regulation of androgen receptor splice variant AR3 by PCGEM1. Oncotarget. 2016 Mar

29;7(13):15481-91. doi: 10.18632/oncotarget.7139. PubMed PMID: 26848868; PubMed

Central PMCID: PMC4941255.

Abstract

The androgen receptor (AR) is required for prostate development and is also a major driver of prostate cancer pathogenesis. Thus androgen deprivation therapy (ADT) is the mainstay of treatment for advanced prostate cancer. However, castration resistance due to expression of constitutively active AR splice variants is a significant challenge to prostate cancer therapy; little is known why effectiveness of ADT can only last for a relatively short time. In the present study, we show that PCGEM1 interacts with splicing factors heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and U2AF65, as determined by RNA precipitation and Western blot, suggesting a role for PCGEM1 in alternative splicing. In support of this possibility, PCGEM1 is correlated with AR3, a predominant and clinically important form of AR splice variants in prostate cancer. Moreover, androgen deprivation (AD) induces PCGEM1 and causes its accumulation in nuclear speckles. Finally, we show that the AD-induced PCGEM1 regulates the competition between hnRNP A1 and U2AF65 for AR pre-mRNA. AD promotes PCGEM1 to interact with both hnRNP A1 and U2AF65 with different consequences. While the interaction of

PCGEM1 with hnRNP A1 suppresses AR3 by exon skipping, its interaction with U2AF65 promotes AR3 by exonization. Together, we demonstrate an AD-mediated AR3 expression involving PCGEM1 and splicing factors.

Conclusions

Expression of AR splice variants is critical to understanding of castration resistance in prostate cancer. In this application, we provide a proof of principle that systematic characterization of AR splice variant regulation is feasible through genome wide KO library. We identify hnRNP A1 as a negative regulator of AR3. In future, we will develop various reporters for other AR splice variant so that it can provide a more comprehensive picture of how AR splice variants are expressed. As a result, this will aid in development of novel strategy for overcoming castration resistance.

Reference:

1. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. *Nature*. 2010;463:364-8.
2. Expert-Bezancon A, Sureau A, Durosay P, Salesse R, Groeneveld H, Lecaer JP, et al. hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B. *The Journal of biological chemistry*. 2004;279:38249-59.

3. Tange TO, Damgaard CK, Guth S, Valcarcel J, Kjems J. The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. *The EMBO journal*. 2001;20:5748-58.
4. Burd CG, Dreyfuss G. RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. *The EMBO journal*. 1994;13:1197-204.

Regulation of androgen receptor splice variant AR3 by PCGEM1

Ziqiang Zhang^{1,2}, Nanjiang Zhou³, Jianguo Huang³, Tsui-Ting Ho¹, Zhuxian Zhu⁴, Zhongmin Qiu², Xinchun Zhou⁵, Chunxue Bai⁶, Fangting Wu⁷, Min Xu⁸, Yin-Yuan Mo¹

¹Department of Pharmacology/Toxicology and Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA

²Department of Pulmonary Medicine, Tongji Hospital, Tongji University, Shanghai, China

³Department of Biochemistry and Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA

⁴Department of Nephrology, Tongji Hospital, Tongji University, Shanghai, China

⁵Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA

⁶Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, PR China

⁷System Biosciences, Mountain View, CA, USA

⁸Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China

Correspondence to: Yin-Yuan Mo, **e-mail:** ymo@umc.edu

Keywords: PCGEM1, hnRNP A1, alternative splicing, androgen receptor, AR splicing variants, AR3, castration resistance, lncRNA

Received: October 06, 2015

Accepted: January 23, 2016

Published: February 02, 2016

ABSTRACT

The androgen receptor (AR) is required for prostate development and is also a major driver of prostate cancer pathogenesis. Thus androgen deprivation therapy (ADT) is the mainstay of treatment for advanced prostate cancer. However, castration resistance due to expression of constitutively active AR splice variants is a significant challenge to prostate cancer therapy; little is known why effectiveness of ADT can only last for a relatively short time. In the present study, we show that PCGEM1 interacts with splicing factors heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and U2AF65, as determined by RNA precipitation and Western blot, suggesting a role for PCGEM1 in alternative splicing. In support of this possibility, PCGEM1 is correlated with AR3, a predominant and clinically important form of AR splice variants in prostate cancer. Moreover, androgen deprivation (AD) induces PCGEM1 and causes its accumulation in nuclear speckles. Finally, we show that the AD-induced PCGEM1 regulates the competition between hnRNP A1 and U2AF65 for AR pre-mRNA. AD promotes PCGEM1 to interact with both hnRNP A1 and U2AF65 with different consequences. While the interaction of PCGEM1 with hnRNP A1 suppresses AR3 by exon skipping, its interaction with U2AF65 promotes AR3 by exonization. Together, we demonstrate an AD-mediated AR3 expression involving PCGEM1 and splicing factors.

INTRODUCTION

Prostate cancer is the most common malignancy among elderly men in Western countries. The androgen receptor (AR) is a nuclear receptor transcription factor required for normal prostate development and prostate cancer pathogenesis. Furthermore, AR serves as an important therapeutic target. For instance, androgen deprivation therapy (ADT) has been the frontline therapy for treatment of advanced prostate cancer. Although initial response of prostate cancer to ADT is effective, these patients inevitably develop the resistance, i.e., castration-

resistant prostate cancer (CRPC) [1, 2]. This is a major obstacle for improving overall survival in prostate cancer. Although this ADT-induced castration resistance has been known for a long time, the underlying mechanism is still elusive. AR is subject to extensive alternative splicing. At least 7 AR splice variants have been identified so far [3, 4]. Among them, AR3 (AR-V7) is one of the major AR splice variants which can play a significant role in castration resistance [5, 6]. More recently, it has been shown that circulating AR3 is associated with the resistance to two clinically important drugs enzalutamide and abiraterone [7].

Alternative splicing represents an important mechanism of genetic diversity in eukaryotes. In this regard, the vast majority of eukaryotic genes including protein-coding genes and long non-coding RNAs (lncRNAs) can be expressed as various alternative splice variants [8] and they may occur in a tissue-specific manner and/or under specific cellular conditions. RNA splicing takes place in a spliceosome, a large and complex molecular machine containing small nuclear ribonucleic particles (snRNPs). Selection of correct splice sites is critical in pre-mRNA splicing and this can be often regulated by various factors. In addition to spliceosome, positive/negative signals such as splicing enhancer/silencer elements in an exon and/or its flanking introns are required for efficient exon recognition, particularly when the exon is alternatively spliced [9, 10]. For example, U2AF65 can bind to exonic splicing enhancer (ESE) or intronic splicing enhancer (ISE) elements to promote exonization. In contrast, heterogeneous nuclear ribonucleoproteins (hnRNPs) such as hnRNP A1 [11] and hnRNP C [12] can bind to exonic splicing silencer (ESS) or intronic splicing silencer (ISS) elements to suppress exonization. However, it remains to be determined which molecular player(s) regulates those interactions to select splice sites in response to environmental cues.

lncRNAs are a large group of poorly characterized non-coding RNAs with >200 nucleotides in length [13]. Accumulating evidence suggests that lncRNAs can play a critical role in regulation of gene expression through various mechanisms [14-16]. Like protein-coding genes, lncRNAs can function as oncogenic and tumor-suppressor genes, thus impacting one or more of the cancer hallmarks. PCGEM1 was identified as a prostate cancer specific lncRNA [17] that is capable of promoting proliferation and

inhibiting apoptosis. However, it remains to be determined whether PCGEM1 can regulate AR alternative splicing in response to ADT, leading to castration resistance.

In the present study, we show that androgen deprivation (AD) induces PCGEM1 expression and causes its subcellular re-distribution. Moreover, PCGEM1 functionally interacts with splicing factors including hnRNP A1 and U2AF65. Of considerable interest, the PCGEM1-hnRNP A1 interaction suppresses binding of hnRNP A1 to AR pre-mRNA whereas the interaction of PCGEM1 with U2AF65 enhances its binding to AR pre-mRNA, leading to expression of AR3.

RESULTS

PCGEM1 interacts with splicing factors hnRNP A1 and U2AF65

PCGEM1 is prostate cancer specific lncRNA [17]. A recent report showed that PCGEM1 and PRNCR1 interact with AR, impacting AR regulated gene expression [18]. However, this may not fully explain why PCGEM1 can promote castration resistance because PCGEM1 can interact with both full-length AR and AR3 [18]. Therefore, we performed RNA precipitation experiments using the biotin-labelled PCGEM1 RNA probe to identify PCGEM1 binding partners. This approach combined with PAGE analysis and mass-spectrometry analysis suggested that heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) was a potential PCGEM1 binding partner (Fig. 1A; Fig. S1). Subsequent Western blot using hnRNP A1 antibody confirmed this interaction (Fig. 1B). Moreover, RNA immunoprecipitation (RIP) using hnRNP A1 antibody




Figure 1: Identification of hnRNP A1 as a PCGEM1 binding partner. **A.** A representative silver-stained gel picture showing a ~37 kDa band specific to PCGEM1 probe. A biotin-labeled PCGEM1 RNA probe was used for the pulldown assay; mass spectrometry analysis indicated that this 37 kDa band is hnRNP A1. ncR-UPAR serves as a negative control. **B.** Verification of the interaction of PCGEM1 with hnRNP A1 by RNA precipitation and Western. Samples were prepared the same way as in Fig. 1A and the membrane was probed with hnRNP A1 antibody. **C.** Detection of PCGEM1 by qRT-PCR after immunoprecipitation with the hnRNP A1 antibody.

detected a 15-fold enrichment of PCGEM1 over IgG (Fig. 1C). Since hnRNP A1 is a splicing factor, the interaction of PCGEM1 with hnRNP A1 may suggest a role for PCGEM1 in AR splicing.

Upregulation of PCGEM1 is associated with AR3 expression and castration resistance in prostate cancer cell lines

It is well known that AR splice variants play a significant role in castration resistance [5, 6]. Next, we determined the role of PCGEM1 in regulation of AR splicing and castration resistance. In this regard, we found a positive correlation of PCGEM1 with AR3, a major splice variant [19], in prostate cancer cell lines. For example, androgen sensitive LNCaP cells expressed the full-length AR whereas AR3 was barely detectable (Fig. 2A). In contrast, castration resistant LNCaP95 and CWR22Rv1 cells expressed both AR3 and the full-length AR. LNCaP95 is an androgen-independent cell line derived from long-term continuous culture of LNCaP cells in androgen-depleted conditions [6]; CWR22Rv1 was derived from xenograft tumors that were serially propagated in mice after castration-induced regression and relapse of the parental androgen-dependent CWR22 xenograft [20]. Apparently, the AR3 level was higher in CWR22Rv1 than in LNCaP95 cells (Fig. 2A). This trend was also seen at the AR3 mRNA level in these cell lines (Fig. 2A, right). Of interest, the PCGEM1 level was also higher in the resistant cell lines CWR22Rv1 and LNCaP95 than in the sensitive LNCaP cells (Fig. 2B). We next determined whether PCGEM1 can promote castration resistance. MTT assays revealed that suppression of PCGEM1 by RNAi sensitized CWR22Rv1 cells to AD (Fig. 2C). Furthermore, suppression of PCGEM1 significantly reduced tumor growth (Fig. S2) and the tumor weight in castrated male mice (Fig. 2D). Together, these results suggest that PCGEM1 is able to promote castration resistance both in vitro and in vivo possibly through regulation of AR3 expression.

Androgen deprivation upregulates PCGEM1 and causes its subcellular re-distribution

Given the positive relationship between PCGEM1 and AR3, we decided to determine whether PCGEM1 specifically impacts AR3 expression, leading to castration resistance. We found that PCGEM1 was significantly induced in LNCaP cells by AD (Fig. 3A). This AD-induced PCGEM1 was dependent on AR status because such induction was not seen in AR negative PC3 and DU-145 cells (Fig. S3). Of interest, levels of PCGEM1 and AR3 are reversible depending on androgen in LNCaP95 cells. For example, PCGEM1 and AR3 (both RNA and protein) were significantly decreased when the cells were put back in androgen-containing

medium (Fig. 3B). Furthermore, FISH assays revealed subcellular re-localization of PCGEM1 in LNCaP cells in response to AD. In the presence of androgen, PCGEM1 was detected in both cytoplasm and nucleus (Fig. 3C, top). This signal was specific to PCGEM1 because the blocking oligo complementary to the probe was able to completely abolish the signal (Fig. S4). As a control, AR was exclusively in the nucleus as expected (Fig. 3C). In the absence of androgen for 2 days, there were more PCGEM1-containing nuclear speckles (Fig. 3C, bottom).

Nuclear speckles are important to RNA splicing and gene expression [21]. To better characterize the subcellular re-distribution of PCGEM1 in response to AD, we grew LNCaP cells in androgen-free medium for up to 28 days. Starting from day 7, we observed the majority PCGEM1 signal in the nucleus, particularly nuclear speckles (Fig. 3D, top). However, AD had little effect on PCGEM1 subcellular localization in CWR22Rv1 cells during 28 days of AD (Fig. 3D, bottom).

hnRNP A1 is a repressor for AR3 expression

Since hnRNP A1 is well-known for its role in mRNA processing or alternative splicing [22, 23], and it may function as a splicing silencer factor [24], we determined whether hnRNP A1 is a negative regulator for AR3 expression. In support of this notion, we identified two putative hnRNP A1 binding sites [25] in the intron between exon 3 (E3) and exon 3b (E3b) (Fig. S5A). Through screening of randomized RNA oligos against hnRNP A1, Burd and Dreyfuss identified an hnRNP A1 winner sequence (UAUGAUAGGGACUUAGGGUG) with two putative binding sites (underlined) [25]. As expected, this A1 winner oligo was able to increase AR3 expression in CWR22Rv1 cells as compared to control oligo (Fig. 4A, left). Moreover, hnRNP A1 siRNA (Fig. 4A, middle) or knockout (Fig. 4A, right) also enhanced AR3 expression in CWR22Rv1 cells, further supporting a suppressive role of hnRNP A1 in AR3 expression. In contrast, PCGEM1 shRNAs suppressed AR3 expression (Fig. 4B).

U2AF65 is an enhancer for AR3 expression

Although other members of hnRNP family such as hnRNP C have been implicated in suppression of alternative splicing of Alu elements [12], RNA precipitation with PCGEM1 probe revealed that PCGEM1 did not interact with hnRNP C (Fig. 5A), suggesting that PCGEM1 specifically interacts with hnRNP A1. However, this assay identified an additional splicing factor U2AF65 that interacted with PCGEM1 (Fig. 5A). U2AF65 is capable of binding to poly-pyrimidine track region of pre-mRNA and it functions as a splicing enhancer factor [26]; In particular, there is a putative U2AF65 binding site (UCUCUCUUUC) in the 3' end of the intron (Fig.

S5A). U2AF65-siRNA suppressed AR3 expression (Fig. 5B), suggesting the importance of U2AF65 in AR3 expression. However, expression levels of hnRNP A1 or U2AF65 were not affected by AD (Fig. 5C). In contrast, AD not only induced PCGEM1 expression (Fig. 3A), but also facilitated the interaction of PCGEM1 with hnRNP A1 and U2AF65, as detected by RIP (Fig. 5D). Of particular interest, such interactions had very different consequences. The increased PCGEM1-hnRNP A1 interaction caused a significant decrease in the ability of hnRNP A1 to interact with AR pre-mRNA (Fig. 5E, left). In contrast, the increased PCGEM1-U2AF65 interaction

promoted its interaction with AR pre-mRNA (Fig. 5E, right), suggesting that along with PCGEM1, hnRNP A1 is capable of suppressing AR3 whereas U2AF65 is capable of promoting AR3.

Androgen deprivation promotes the co-localization of PCGEM1 with U2AF65 in nuclear speckles

Nuclear speckles have been shown to be critical sites for RNA processing [21]. AD caused accumulation of PCGEM1 in the nuclear speckles (Fig. 3D) in addition




Figure 2: Effect of PCGEM1 on castration resistance. **A.** Relative expression of AR, AR variants (AR-v) and AR3 in LNCaP, LNCaP95 and CWR22Rv1 cells, as detected by Western (left) using N-terminal AR antibody or AR3 specific antibody; and AR3 mRNA levels, as detected by qRT-PCR (right) using AR3 specific primers (AR3-RT-5.1 and AR3-RT-3.1). β -actin was used as an internal control. **B.** Expression of PCGEM1 by qRT-PCR in LNCaP, LNCaP95 and CWR22Rv1 cells. **C.** PCGEM1-shRNA suppresses CWR22Rv1 cell growth. The cells were grown in androgen-free medium and the cell growth was measured for 4 days by MTT. **D.** PCGEM1-shRNA reduces tumor growth in the xenograft mouse model. CWR22Rv1 cells were injected into castrated male SCID mice subcutaneously as described in the text, and tumor growth was measured 7 days after injection. Tumors were harvested and weighted at day 31 after injection of tumor cells. 1, Ctrl shRNA; 2, PCGEM1-shRNA. Values in A, B and D are means \pm SE (n = 3). **, p < 0.01, two-sided two-sample t test.

to upregulation of the PCGEM1 level (Fig. 3A). Before AD, a relatively low level of U2AF65 was detected in nuclear speckles. Under AD for 7 days, more U2AF65 was accumulated in the nuclear speckles in LNCaP cells (Fig. 6A). Similarly, a fair amount of PCGEM1 was found in these nuclear speckles, co-localizing with U2AF65 (Fig. 6A, left). In CWR22Rv1 cells, androgen had little effect on the subcellular localization of PCGEM1 or U2AF65 (Fig. 6A, right). Of interest, this androgen-mediated redistribution of PCGEM1 and U2AF65 was also reversible in LNCaP95 cells. For example, upon addition of androgen to the medium, nuclear speckle staining for both PCGEM1 and U2AF65 remarkably decreased (Fig. 6B).

The binding sites of hnRNP 1 and U2AF65 are required for expression of AR3 reporters

To further determine the role of PCGEM1 in AR3 expression, we generated a mini-gene cassette reporter carrying mCherry (Fig. S5A). As expected, mCherry signal was higher in CWR22Rv1 cells than in LNCaP cells (Fig. S5B). Ectopic expression of PCGEM1 increased the signal in LNCaP cells (Fig. S5C). To determine the role of the hnRNP A1 and U2AF65 binding sites in AR3 expression, we mutated these sites separately (Fig. 6C). As shown in Fig. 6D and Fig. S6, mutation of hnRNP A1 binding sites at AR pre-mRNA increased the mCherry signal. In contrast, mutation of the U2AF65 binding site abolished




Figure 3: Androgen deprivation induces PCGEM1 expression and its subcellular re-localization. **A.** AD induces PCGEM1 in LNCaP cells. The cells were cultured in the presence or absence of androgen for 7 days before harvesting for qRT-PCR. **B.** Reversible regulation of PCGEM1 and AR3 in LNCaP95 cells in response to AD. The cells that were originally maintained in androgen-free were switched to medium supplemented with 10 nM R1881 and grown for 2 days. The cells were then harvested for qRT-PCR (left) to detect PCGEM1 and AR3 RNA or Western (right) to detect AR3 at the protein level. **C.** Subcellular distribution of PCGEM1 in response to androgen. PCGEM1 was detected by FISH and AR was detected by IF. LNCaP cells were grown in androgen containing medium (top) or in androgen free medium for 2 days (bottom) before fixation for FISH and IF. **D.** Subcellular distribution of PCGEM1 in response to AD. Cells were fixed and PCGEM1 was detected by FISH. Only day 0 was shown for CWR22Rv1 because the distribution of PCGEM1 was same from day 0, day7 and day 28. Values in A and B are means \pm SE (n = 3). **, p < 0.01, two-sided two-sample t test.

the signal. These results are consistent with the finding that interactions of PCGEM1-hnRNP A1 and PCGEM1-U2AF65 have different consequences (Fig. 5D-5E).

DISCUSSION

The present study demonstrates that AD induces PCGEM1 and causes its localization of nuclear speckles. Through interaction with splicing factors, such as hnRNP A1 and U2AF65, PCGEM1 promotes AR3 expression. As a major AR splice variant, AR3 has been shown to play a significant role in castration resistance [27] and thus identification of this AD-PCGEM1-AR3 axis may explain in part why the effectiveness of ADT can only last for a relatively short time. Our study suggests that PCGEM1 participates in the AR signaling by regulation of AR splice variants in response to AD. Moreover, our *in vitro* and xenograft assays with castrated male mice support the role of PCGEM1 in castration resistance. Together, these findings highlight the importance of PCGEM1 in AR signaling and castration resistance.

As components of the basic machinery for RNA splicing, hnRNP A1 and U2AF65 are important to AR3 expression although AD has no effect on their expression levels. The hnRNP proteins belong to the RNA binding protein family that play multiple functions. Along with other RNP proteins, they participate in pre-mRNA processing such as splicing, and are important determinants of mRNA export, localization, translation, and stability [28]. Several members of this family have been implicated in alternative splicing. In this regard, it appears that a specific member of these proteins may be responsible for a specific set of gene splicing. For instance, hnRNP C can compete with U2AF65 to

specifically suppress splicing of Alu exons [12]. We show that hnRNP C does not interact with PCGEM1. This may be attributed to the ability of hnRNP C to preferably bind poly uridine regions [12]. In contrast, hnRNP A1 tends to bind relatively purine-rich regions (e.g., UAGGGA/U). This finding is consistent with the report that hnRNP C has little overlap with hnRNP A1 or other members of hnRNP protein except for hnRNP I which has a slight overlap [12]. Of interest, genetic mutations at hnRNP C binding sites play a major role in exonization of Alu exon, leading to various diseases. Thus, it is possible that PCGEM1 may play a similar role. AD-induced PCGEM1 and its subcellular redistribution provide more flexibility of AR3 regulation. Therefore, like genetic mutations, environmental cue offers additional mechanisms for alternative splicing.

Regulation of alternative splicing is a complex process. It is known that splicing factors select splice sites often in a concentration-dependent manner and thus, the relative expression of these factors may decide a particular splice pattern [29]. The present study suggests that this can be achieved by AD-mediated PCGEM1. For instance, AD increases the interaction of PCGEM1 with hnRNP A1 and U2AF65 (Fig. 5D). Once bound by PCGEM1, the binding activity of hnRNP A1 to AR pre-mRNA is reduced; on the other hand, the binding activity of U2AF65 to AR pre-mRNA is increased. In support of this notion, we show that AD promotes the localization of U2AF65 in nuclear speckles (Fig. 6A). In particular, this redistribution seems to be closely associated with PCGEM1. However, in resistant CWR22Rv1 cells, such redistribution of U2AF65 is not obvious, which may be explained by the possibility that CWR22Rv1 cells preferably form a PCGEM1-




Figure 4: Regulation of AR3 by hnRNP A1 and PCGEM1. **A.** Increasing AR3 expression by A1 winner, hnRNP A1-siRNA or hnRNP A1 knockout. CWR22Rv1 cells were transiently transfected with A1 winner oligo or hnRNP A1-siRNAs and were then harvested 2 days later for Western. hnRNP A1 knockout was made through CRISPR/Cas9 as described in the text. **B.** Suppression of PCGEM1 by RNAi reduces AR3 expression in CWR22Rv1 cells.

U2AF65-AR pre-mRNA complex, leading to constitutive expression of AR3.

However, the detail mechanism still remains to be determined as to why the PCGEM1-hnRNP A1 interaction causes the loss of its suppressive function whereas the PCGEM1-U2AF65 interaction promotes the binding of U2AF65 to AR pre-mRNA, leading to expression of AR3. We speculate at least two possibilities for this opposing role of PCGEM1 once bound by these splicing factors. Although hnRNP A1 is a RNA binding protein, interacting with many types of RNAs, several reports suggest that hnRNP A1 prefer the UAG motif [25, 30]. For instance, screening randomized oligos identified several oligos that are preferably bound by hnRNP A1 and among them A1 winner oligo is the top

preferable site [25]. There are two conserved A1 binding in AR intron between E3 and E3b. We show that these two binding sites are important because mutation of these two sites causes a significant increased mCherry signal. On the other hand, although PCGEM1 does not carry these conserved binding sites, there are over 10 UAG motifs through which PCGEM1 may compete with AR pre-mRNA for hnRNP A1. Our RIP assay with hnRNP A1 antibody supports this possibility. Another possibility is that binding of PCGEM1 to U2AF65 may enhance its competition with hnRNP A1 for AR pre-mRNA. Once bound by PCGEM1, U2AF65 may become more competitive. Through the similar mechanism, PCGEM1 might also be involved in regulation of other AR splice variants.




Figure 5: PCGEM1-hnRNP A1 interaction suppresses, whereas PCGEM1-U2AF65 interaction enhances AR3 expression. **A.** PCGEM1 interacts with hnRNP A1 and U2AF65, but not hnRNP C, as determined by RNA precipitation and Western. **B.** Suppression of U2AF causes reduction of AR variants (AR-v). **C.** No difference is seen for hnRNP A1 or U2AF expression between LNCaP and CWR22Rv1 cells in the presence or absence of androgen. **D.** AD enhances the interaction of PCGEM1 with hnRNP A1 and U2AF. **E.** While the interaction of hnRNP A1 with AR pre-mRNA is decreased after AD, the interaction of U2AF65 with AR pre-mRNA is increased. Values in D and E are means \pm SE (n = 3). **, p < 0.01, two-sided two-sample t test.

PCGEM1 is an interesting molecule, but the role of PCGEM1 in prostate cancer is still controversial. For example, it has been reported that PCGEM1 along with PRNCR1 can impact AR signaling through interaction with AR to promote castration resistance [18], however, a comprehensive analysis of RNA-sequencing data (RNA-seq) does not support this notion [31]. Similarly, a recent study suggests that PCGEM1 is stimulated by androgen and downregulated by castration in xenograft models [32], which is inconsistent with our findings. Furthermore, their study showed no subcellular distribution of PCGEM1 in response to AD. Although this might be due to different

systems used in these studies, such a controversy will certainly stimulate further investigations.

In summary, our study suggests that the interaction of PCGEM1 with splicing factors such as hnRNP A1 and U2AF65 determines the fate of AR3 (Fig. S7). One function of hnRNP A1 is to interact with AR pre-mRNA at hnRNP A1 binding sites, which subsequently inhibits the binding to AR pre-mRNA by splicing enhancers such as U2AF65 under normal physiological conditions. However, AD causes upregulation of PCGEM1 (Fig. 3A) and increases the accumulation of PCGEM1 in nuclear speckles (Fig. 3D). Thus, more PCGEM1 interacts with




Figure 6: Co-localization of PCGEM1 and U2AF65 in nuclear speckles and the role of the binding sites of hnRNP A1 and U2AF65 in AR3 expression. **A.** U2AF65 and PCGEM1 are co-localized in nuclear speckles in response to AD in LNCaP cells (left). However, AD has no effect on this co-localization in CWR22Rv1 cells (right). **B.** Reversible nuclear speckle localization of PCGEM1 in LNCaP95 cells in response to androgen. The cells were maintained in androgen-free medium and then switched to androgen-containing medium for 2 days. **C & D.** Binding sites for hnRNP A1 and U2AF65 in AR pre-mRNA are important to AR3 expression. CWR22Rv1 cells were transfected with mini-gene cassette reporters as indicated (C) and mCherry signals were examined 24 h after transfection. Relative expression of mCherry signals by randomly examining 10 fields and then normalized as 100% for AR3 wild type reporter. Values in (D) are means \pm SE (n = 3). **, p < 0.01, two-sided two-sample t test.

hnRNP A1 and U2AF65 (Fig. 5D), which, however, can have opposite consequences. Once bound by PCGEM1, hnRNP A1 is no longer able to interact with AR pre-mRNA (Fig. 5E) to suppress U2AF65 binding to AR pre-mRNA. On the other hand, the ability of the PCGEM1-bound U2AF65 to interact with AR pre-mRNA is increased, facilitating their co-localization in nuclear speckles (Fig. 5E) and promoting AR3 expression and castration resistance.

MATERIALS AND METHODS

Cell culture

Prostate cancer LNCaP and CWR22Rv1 cells were purchased from ATCC; LNCaP95 was a generous gift from Dr. Alan K. Meeker, Johns Hopkins University School of Medicine. Cells were grown in phenol free RPMI 1640 (Lonza, Walkersville, MD) supplemented with charcoal stripped 5% FBS (Sigma-Aldrich). HECK293T cells were grown in DMEM supplemented with charcoal stripped 10% FBS. All media were supplemented with 2 mM glutamine, 100 units of penicillin/ml, and 100 µg of streptomycin/ml (Lonza). Cells were incubated at 37°C and supplemented with 5% CO₂ in the humidified chamber.

Lentivirus preparation and infection

Lentiviral packaging was carried out in HEK-293T cells using a packaging system from SBI per the manufacturer's protocol, as described previously [33]. For infection, exponentially growing cells were mixed with viral particles in the presence of polybrene (0.8 mg/ml) in a six-well plate at a multiplicity of infection of 1~3.

RNA precipitation

To determine which proteins are associated with PCGEM1, we performed RNA precipitation assay using synthesized PCGEM1 as a probe. In brief, the DNA fragment covering the entire PCGEM1 sequence was amplified by PCR using a T7 containing primers (T7-PCGEM1-5.1 and T7-PCGEM1-NotI-3.1), and then cloned into pCR8 (Life Technology). In addition, two lncRNAs, ncR-UPAR and HULC, were also cloned in the same way as negative controls. The resultant plasmid DNA was linearized with restriction enzyme Not I which was introduced from the reverse PCR primer, and then used to synthesize RNA by T7 polymerase. A 20 µl reaction contained 400 ng linearized plasmid DNA, 20 U ribonuclease inhibitor, 2.5 mM NTP mixture supplemented with 10% biotin labeled UTP (Perkin Elmer) and 20 U T7 RNA polymerase (New England BioLabs); and then it was incubated at 37°C for 60 min, followed by 25 U RNase-free DNase I (New England BioLabs) at 37°C for

30 min. The labeled RNA was purified by a column-based kit (Zymo Research). Cellular extract was prepared from a 10 cm dish culture (~80% confluence) with cell lysis buffer [34]. For precipitation assays, the reaction (RNA probe and cellular extract) was incubated at 4°C for 60 min, followed by 5 washes with PBS. The pellets were used either for extraction of RNA for RT-PCR or for Western according to standard procedures.

RNA immunoprecipitation (RIP)

To determine the interaction of hnRNP A1 or U2AF65 with PCGEM1 and AR pre-mRNA, we used hnRNP A1 or U2AF65 antibody for pulldown assays and then detected PCGEM1 or AR pre-mRNA by qRT-PCR using specific primers listed in Supplementary Table 1. Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore) was used for RIP procedures according to the manufacturer's protocol. After the antibody was recovered by protein A+G beads, standard qRT-PCR was performed to detect RNA levels in the precipitates.

Fluorescence in situ hybridization (FISH)

FISH was used to detect PCGEM1 levels in prostate cancer cell lines. Biotin-labeled antisense LNA probes derived from PCGEM1 were listed in Supplementary Table 1. The procedure was essential as previously described [35] except that signals were revealed by TSA™ Kit #24 with Alexa Fluor 568 (Life Technology).

Immunofluorescence staining

Immunofluorescence staining was used to detect AR, hnRNP A1 and U2AF65, as described previously [34]. In brief, cells were 3% paraformaldehyde and permeabilized by 80% cold methanol. After washing with PBS (phosphate buffered saline), coverslips were then incubated in PBS with 3% BSA for 10 min at room temperature. Primary antibodies against individual protein in PBST (PBS plus 0.1% Tween 20) were then added and incubated for 1 h at room temperature. After 3 washes with PBS, the cells were incubated with a fluorescence-conjugated secondary antibody conjugated with either Alexa Fluor 568 or Alexa Fluor 488 in the dark for 1 h. For nuclear staining, the cells were subsequently stained in 0.5 µg/ml Hoechst dye for 5 min before examinations under a fluorescence microscope.

MTT assay

MTT assay was performed to determine the effect of PCGEM1 knockdown on cell growth as described previously [34]. Infected CWR22Rv1 cells carrying control shRNA or PCGEM1-siRNAs were grown in regular medium and the relative cell growth was daily measured from day 0 to day 4.

Xenograft mouse model

The animal studies were conducted in accordance with NIH animal use guidelines and the experimental protocol was approved by the UMMC's Animal Care and Use Committee. Male SCID mice at 5~6 week old were first castrated and one week later infected CWR22Rv1 cells (control shRNA or PCGEM1-shRNAs) were then injected subcutaneously into these mice with 1 million cells containing 50% matrigel per spot, two spots per animal and 6 animals per group. Tumor growth was monitored every other day and harvested at day 31 after injection. The two-group t test was used to compare two means at each time point. All animals were included for analysis.

Knockout of hnRNP A1 by CRISPR/Cas9

To facilitate the selection of positive clones resulted from CRISPR/Cas9, we generated a donor vector in such a way that targeting sequence is replaced by marker genes (GFP and PU, the puromycin resistance gene) once it is integrated into the genomic DNA by homologous recombination. Donor vector carried ~800 bp targeting sequence at each side and EF1-GFP-T2A-PU in the middle, flanked by a LoxP site. The dual gRNA construct carrying Cas9 and donor vector were introduced into CWR22Rv1 cells by transient transfection. One week later, the transfected cells were subject to puromycin selection; and surviving cells were sorted by FACS based on GFP signal into individual wells of 96-well plates and incubated for 2~3 weeks, as described previously [36]. The sorted clones were then expanded in 24 well plates. Complete knockout clones were identified by genomic PCR and Western.

Statistical analysis

The two-sample t test was used to compare two mean expressions. Bonferroni correction was used to adjust the p values of pairwise comparisons among three mean expressions. Relationship between PCGEM-1 and AR expression was studied by depicting scatter plot and calculating Pearson correlation coefficient. All p values were two sided and p values less than 0.05 were considered as significant.

ACKNOWLEDGMENTS

We thank Dr. Alan Meeker (Johns Hopkins School of Medicine) for providing LNCaP95 cells. This work was in part supported by NIH grant R01 CA154989 (Y.M.) and Department of Defense Prostate Cancer Research Program grants PC110379 and PC141083 (Y.M.) and National Natural Science Foundation of China (NSFC) grant No. 81372513 (Z.Z.) and Shanghai Pujiang Program of China grant No.15PJ1407500 (Z.Z.).

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

Abbreviations

AR, androgen receptor; IF, immunofluorescence; FISH, fluorescence in situ hybridization; hnRNP, heterogeneous nuclear ribonucleoprotein; lncRNA, long non-coding RNA; PCR, polymerase chain reaction; RT, reverse transcription; RIP, RNA immunoprecipitation; qRT-PCR, quantitative RT-PCR.

REFERENCES

1. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. *The New England journal of medicine*. 2004; 351:1488-1490.
2. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. *Nature medicine*. 2004; 10:33-39.
3. Guo Z, Qiu Y. A new trick of an old molecule: androgen receptor splice variants taking the stage?! *International journal of biological sciences*. 2011; 7:815-822.
4. Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. *The Journal of biological chemistry*. 2011; 286:36152-36160.
5. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer research*. 2009; 69:16-22.
6. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. *Cancer research*. 2012; 72:3457-3462.
7. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *The New England journal of medicine*. 2014; 371:1028-1038.
8. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nature genetics*. 2008; 40:1413-1415.
9. Wang Z, Xiao X, Van Nostrand E, Burge CB. General and specific functions of exonic splicing silencers in splicing control. *Molecular cell*. 2006; 23:61-70.

10. Graveley BR, Hertel KJ, Maniatis T. The role of U2AF35 and U2AF65 in enhancer-dependent splicing. *RNA*. 2001; 7:806-818.
11. Kashima T, Rao N, David CJ, Manley JL. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. *Human molecular genetics*. 2007; 16:3149-3159.
12. Zarnack K, Konig J, Tajnik M, Martincorena I, Eustermann S, Stevant I, Reyes A, Anders S, Luscombe NM, Ule J. Direct competition between hnRNP C and U2AF65 protects the transcriptome from the exonization of Alu elements. *Cell*. 2013; 152:453-466.
13. Xie C, Yuan J, Li H, Li M, Zhao G, Bu D, Zhu W, Wu W, Chen R, Zhao Y. NONCODEv4: exploring the world of long non-coding RNA genes. *Nucleic acids research*. 2014; 42:D98-103.
14. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet*. 2009; 10:155-159.
15. Wang KC, Chang HY. Molecular Mechanisms of Long Noncoding RNAs. *Mol Cell*. 2011; 43:904-914.
16. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. *Cell*. 2013; 154:26-46.
17. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S. PCGEM1, a prostate-specific gene, is over-expressed in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97:12216-12221.
18. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Da M, Zhang J, Evans CP, Rosenfeld MG. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. *Nature*. 2013; 500:598-602.
19. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:16759-16765.
20. Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. *In vitro cellular & developmental biology Animal*. 1999; 35:403-409.
21. Spector DL, Lamond AI. Nuclear speckles. *Cold Spring Harbor perspectives in biology*. 2011; 3. pii: a000646.
22. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. *Nature*. 2010; 463:364-368.
23. Expert-Bezancon A, Sureau A, Durosay P, Salesse R, Groeneveld H, Lecaer JP, Marie J. hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B. *The Journal of biological chemistry*. 2004; 279:38249-38259.
24. Tange TO, Damgaard CK, Guth S, Valcarcel J, Kjems J. The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. *The EMBO journal*. 2001; 20:5748-5758.
25. Burd CG, Dreyfuss G. RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. *The EMBO journal*. 1994; 13:1197-1204.
26. Tronchere H, Wang J, Fu XD. A protein related to splicing factor U2AF35 that interacts with U2AF65 and SR proteins in splicing of pre-mRNA. *Nature*. 1997; 388:397-400.
27. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. *Cancer research*. 2009; 69:2305-2313.
28. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. *Nature reviews Molecular cell biology*. 2002; 3:195-205.
29. van der Houven van Oordt W, Diaz-Meco MT, Lozano J, Krainer AR, Moscat J, Caceres JF. The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. *The Journal of cell biology*. 2000; 149:307-316.
30. Kashima T, Rao N, Manley JL. An intronic element contributes to splicing repression in spinal muscular atrophy. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:3426-3431.
31. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. *Oncotarget*. 2014; 5:1434-1438.
32. Parolia A, Crea F, Xue H, Wang Y, Mo F, Ramnarine VR, Liu HH, Lin D, Saidy NR, Clermont PL, Cheng H, Collins C, Helgason CD. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. *Molecular cancer*. 2015; 14:46.
33. Sachdeva M, Liu Q, Cao J, Lu Z, Mo YY. Negative regulation of miR-145 by C/EBP-beta through the Akt pathway in cancer cells. *Nucleic acids research*. 2012; 40:6683-6692.
34. Wu F, Chiocca S, Beck WT, Mo YY. Gam1-associated alterations of drug responsiveness through activation of apoptosis. *Molecular cancer therapeutics*. 2007; 6:1823-1830.
35. Gupta A, Mo YY. Detection of microRNAs in cultured cells and paraffin-embedded tissue specimens by in situ hybridization. *Methods Mol Biol*. 2011; 676:73-83.
36. Ho TT, Zhou N, Huang J, Koirala P, Xu M, Fung R, Wu F, Mo YY. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. *Nucleic acids research*. 2015; 43:e17.